Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review

Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study find...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Duo Lan, Siying Song, Yunhuan Liu, Baolian Jiao, Ran Meng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	batroxobin vascular disease ischemic effects mechanism Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/c1ee97a1c6c34a2fa2d3efc85e1567bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c1ee97a1c6c34a2fa2d3efc85e1567bb
record_format	dspace
spelling	oai:doaj.org-article:c1ee97a1c6c34a2fa2d3efc85e1567bb2021-12-02T11:28:12ZUse of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review1664-229510.3389/fneur.2021.716778https://doaj.org/article/c1ee97a1c6c34a2fa2d3efc85e1567bb2021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fneur.2021.716778/fullhttps://doaj.org/toc/1664-2295Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study findings about batroxobin on correcting cerebral arterial, venous, and peripheral vascular diseases, to explore the mechanism of batroxobin on anti-thrombosis process.Methods: A thorough literature search was conducted utilizing the PubMed Central (PMC) and EMBASE databases to identify studies up to June 2021. Data from clinical studies and animal experiments about batroxobin were extracted, integrated and analyzed based on Cochrane handbook for systematic reviews of interventions approach and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P), including the condition of subjects, the usage and dosage, research observation index and main findings.Results: A total of 62 studies were enrolled in this systematic review, including 26 clinical studies and 36 animal experiments. The 26 clinical studies involved 873 patients with arterial ischemic events, 92 cases with cerebral venous thrombosis, 13 cases with cerebral cortical vein thrombosis, and 1,049 cases with peripheral vascular diseases. These patients included 452 males and 392 females aged 65.6 ± 5.53 years. The results revealed that batroxobin had broad effects, including improving clinical prognosis (n = 12), preventing thrombosis (n = 7), promoting thrombolysis (n = 6), and improving vascular cognitive dysfunction (n = 1). The effects of batroxobin on reducing neuronal apoptosis (n = 8),relieving cellular edema (n = 4), improving spatial memory (n = 3), and promoting thrombolysis (n = 13) were concluded in animal experiments. The predominant mechanisms explored in animal experiments involved promoting depolymerization of fibrinogen polymers (n = 6), regulating the expression of related molecules (n = 9); such as intercellular adhesion molecule, heat shock proteins, tumor necrosis factor), reducing oxidative stress (n = 5), and reducing inflammation response (n = 4).Conclusion: Batroxobin can correct both arterial and venous ischemic diseases by promoting depolymerization of fibrinogen polymers, regulating the expression of related molecules, reducing oxidative stress, and reducing the inflammation response.Duo LanDuo LanDuo LanSiying SongSiying SongSiying SongYunhuan LiuBaolian JiaoBaolian JiaoBaolian JiaoRan MengRan MengRan MengFrontiers Media S.A.articlebatroxobinvascular diseaseischemiceffectsmechanismNeurology. Diseases of the nervous systemRC346-429ENFrontiers in Neurology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	batroxobin vascular disease ischemic effects mechanism Neurology. Diseases of the nervous system RC346-429
spellingShingle	batroxobin vascular disease ischemic effects mechanism Neurology. Diseases of the nervous system RC346-429 Duo Lan Duo Lan Duo Lan Siying Song Siying Song Siying Song Yunhuan Liu Baolian Jiao Baolian Jiao Baolian Jiao Ran Meng Ran Meng Ran Meng Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
description	Background and Purpose: The mechanism of action of Batroxobin included the decomposition of the fibrinogen to fibrin degradation products (FDPs) and D-dimer and mobilization of endothelial cells to release endogenous nt-PA and to promote thrombolysis. This review aims to summarize current study findings about batroxobin on correcting cerebral arterial, venous, and peripheral vascular diseases, to explore the mechanism of batroxobin on anti-thrombosis process.Methods: A thorough literature search was conducted utilizing the PubMed Central (PMC) and EMBASE databases to identify studies up to June 2021. Data from clinical studies and animal experiments about batroxobin were extracted, integrated and analyzed based on Cochrane handbook for systematic reviews of interventions approach and the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P), including the condition of subjects, the usage and dosage, research observation index and main findings.Results: A total of 62 studies were enrolled in this systematic review, including 26 clinical studies and 36 animal experiments. The 26 clinical studies involved 873 patients with arterial ischemic events, 92 cases with cerebral venous thrombosis, 13 cases with cerebral cortical vein thrombosis, and 1,049 cases with peripheral vascular diseases. These patients included 452 males and 392 females aged 65.6 ± 5.53 years. The results revealed that batroxobin had broad effects, including improving clinical prognosis (n = 12), preventing thrombosis (n = 7), promoting thrombolysis (n = 6), and improving vascular cognitive dysfunction (n = 1). The effects of batroxobin on reducing neuronal apoptosis (n = 8),relieving cellular edema (n = 4), improving spatial memory (n = 3), and promoting thrombolysis (n = 13) were concluded in animal experiments. The predominant mechanisms explored in animal experiments involved promoting depolymerization of fibrinogen polymers (n = 6), regulating the expression of related molecules (n = 9); such as intercellular adhesion molecule, heat shock proteins, tumor necrosis factor), reducing oxidative stress (n = 5), and reducing inflammation response (n = 4).Conclusion: Batroxobin can correct both arterial and venous ischemic diseases by promoting depolymerization of fibrinogen polymers, regulating the expression of related molecules, reducing oxidative stress, and reducing the inflammation response.
format	article
author	Duo Lan Duo Lan Duo Lan Siying Song Siying Song Siying Song Yunhuan Liu Baolian Jiao Baolian Jiao Baolian Jiao Ran Meng Ran Meng Ran Meng
author_facet	Duo Lan Duo Lan Duo Lan Siying Song Siying Song Siying Song Yunhuan Liu Baolian Jiao Baolian Jiao Baolian Jiao Ran Meng Ran Meng Ran Meng
author_sort	Duo Lan
title	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_short	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_full	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_fullStr	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_full_unstemmed	Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review
title_sort	use of batroxobin in central and peripheral ischemic vascular diseases: a systematic review
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/c1ee97a1c6c34a2fa2d3efc85e1567bb
work_keys_str_mv	AT duolan useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT duolan useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT duolan useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT siyingsong useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT siyingsong useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT siyingsong useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT yunhuanliu useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT baolianjiao useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT baolianjiao useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT baolianjiao useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT ranmeng useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT ranmeng useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview AT ranmeng useofbatroxobinincentralandperipheralischemicvasculardiseasesasystematicreview
_version_	1718395903211995136

Use of Batroxobin in Central and Peripheral Ischemic Vascular Diseases: A Systematic Review

Ejemplares similares